Insider Trading Roundup: Viveve Medical, Inc. $VIVE

invest-1346104_1920

Viveve Medical, Inc. (VIVE) insider have most recently took part in a trading activity. On Aug 23, 2017 Durbin Scott, CFO bought 5,000 shares having total worth of $26,250 at the price of $5.25 per share, following the transaction a total of 11,568 shares owned by Durbin Scott.

Furthermore, over the past 12 months , the stock was traded 4 times by insiders. an employee of the company was the buyer in 4 instances.

Shares of Viveve Medical, Inc. (VIVE) traded up 1.96% on Aug 22, 2017, hitting $5.2. 182,550 shares of the company’s stock traded hands. Viveve Medical, Inc. has a 52 week low of $3.99 and a 52 week high of $9.38. The company’s market cap is $77 million.

Viveve Medical, Inc. (VIVE) last announced its earnings results on Aug 10, 2017. The company reported -0.54 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.43 by $0.11. The company had revenue of $3 million for the quarter, compared to the consensus estimate of $3 million. During the same quarter in the previous year, the company posted -0.66 earnings per share. The company’s revenue for the quarter was up 98% on a year-over-year basis.

2017-08-10 2017-05-11 2017-02-16 2016-11-10 2016-08-11
earnings per share -0.54 -0.57 -0.55 -0.46 -0.66
Revenue(M) 3.08 3.04 2.45 1.85 1.56

PLC Systems was incorporated in British Columbia, Canada on March 3, 1987. The company is a medical device company specializing in innovative technologies for the cardiac and vascular markets. Its newest marketable product is RenalGuard. RenalGuard is designed to reduce the potentially toxic effects that contrast media can have on the kidneys when it is administered to patients during certain medical imaging procedures. The RenalGuard System consists of a proprietary, patented console and accompanying single-use sets. It operates by first collecting and measuring patient urine outputs and then in real-time precisely matching these urine outputs with a prescribed replacement fluid by means of intravenous infusion. The company obtained a CE Mark for RenalGuard in December 2007 and began its initial commercialization efforts in the European Union (‘EU’) in Italy in April 2008. RenalGuard is subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and abroad.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.